Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis
Author links open overlay panelAkosua AdomAgyemanBPharm, MSc1KenLee ChinBPharm (Hons), MClinPharm, PhD23Cornelia B.LandersdorferBPharm, PhD1DannyLiewMBBS (Hons), BMedSc, FRACP, PhD2RichardOfori-AsensoBPharm, MSc, PhD24
https://doi.org/10.1016/j.mayocp.2020.05.030
Abstract
Objective
To estimate the prevalence of olfactory and gustatory dysfunctions (OGDs) among patients infected with novel coronavirus disease 2019 (COVID-19).
Patients and Methods
A systematic review was conducted by searching MEDLINE, EMBASE, and the preprint server MedRxiv until 11 May 2020 using the terms ‘anosmia’ or ‘hyposmia’ or ‘dysosmia’ or ‘olfactory dysfunction’ or ‘olfaction disorder’ or ‘smell dysfunction’ or ‘ageusia’ or ‘hypogeusia’ or ‘dysgeusia’ or ‘taste dysfunction’ or ‘gustatory dysfunction’ or ‘neurological’ and ‘COVID-19’ or ‘2019 novel coronavirus’ or ‘2019-nCoV’ or ‘SARS-CoV-2’. References of included studies were also manually screened. Only studies involving diagnostic-confirmed patients with COVID-19 were included. Random-effects meta-analysis was performed.
